A major response to trabectedin in metastatic malignant fibrous histiocytoma of the vertebra: a case report and review of the literature.
Tumori. 2013 Mar-Apr;99(2):e43-8
Authors: Sereno M, Merino M, Aguayo C, Hernández S, Gutiérrez-Gutiérrez G, Zambrana Tévar F, López-Gómez M, Gómez Raposo C, Casado-Sáenz E
Malignant fibrous histiocytoma is an aggressive tumor, the most common soft-tissue sarcoma of adult age. It is usually located in the extremities and retroperitoneum, and very rarely there is skeletal involvement. Surgery is the preferred treatment in early disease; in advanced disease, chemotherapy is the main therapeutic strategy. We present a 25-year-old female patient diagnosed with a vertebral mass in T5 with a severely compromised spinal cord. She underwent surgical decompression and the pathological findings were consistent with malignant fibrous histiocytoma. After several surgical treatments she had pulmonary progression and was therefore started on chemotherapy. She had a very poor response to most of the administered regimens until she initiated trabectedin 1 mg/m 2 every three weeks. She showed a significant improvement with a major response of the lung metastases. This report indicates that trabectedin is an active drug in advanced, previously treated metastatic malignant fibrous histiocytoma.
PMID: 23748828 [PubMed – indexed for MEDLINE]